An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria
- 1 August 2002
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 54 (2) , 140-146
- https://doi.org/10.1046/j.1365-2125.2002.01620.x
Abstract
Aims To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of betaine in the treatment of classical homocystinuria due to cystathionine β‐synthase (CβS) deficiency with a view to optimizing the dosage regimen.Methods Betaine was given as a single oral dose of 100 mg kg−1 to six patients (age range 6–17 years) who normally received betaine but whose treatment had been suspended for 1 week prior to the study. Plasma betaine and total homocysteine concentrations were measured by high performance liquid chromatography (h.p.l.c.) at frequent intervals over 24 h. The best‐fit PK model was determined using the PK‐PD program Win‐Nonlin and the concentration‐time‐effect data analysed by an indirect PD model. Using the PK and PD parameters, simulations were carried out with the aim of optimizing betaine dosage.Results Betaine PK was described by both mono‐ and bi‐exponential disposition functions with first order absorption and a lag time. The correlation coefficient between betaine oral clearance and body weight was 0.6. Mean betaine clearance was higher in males than in females (P=0.03). PK‐PD simulation indicated minimal benefit from exceeding a twice‐daily dosing schedule and a 150 mg kg−1 day−1 dosage for betaine.Conclusions PK‐PD modelling allows recommendations for optimal dosage of betaine in the treatment of homocystinuria, that have the potential for improved patient compliance and both therapeutic and pharmacoeconomic benefit.Keywords
This publication has 23 references indexed in Scilit:
- Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuriaBritish Journal of Clinical Pharmacology, 2003
- Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolismMetabolism, 1993
- Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency.Archives of Disease in Childhood, 1989
- A closer look at the eye in homocystinuria: A screened populationJournal of Inherited Metabolic Disease, 1988
- Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuriaThe Journal of Pediatrics, 1988
- The effect of oral betaine on vertebral body bone density in pyridoxine‐non‐responsive homocystinuriaJournal of Inherited Metabolic Disease, 1987
- Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiencyEuropean Journal of Pediatrics, 1984
- Homocystinuria — The Effects of Betaine in the Treatment of Patients Not Responsive to PyridoxineNew England Journal of Medicine, 1983
- TREATMENT OF HOMOCYSTINURIA WITH A LOW-METHIONINE DIET, SUPPLEMENTAL CYSTINE, AND A METHYL DONORThe Lancet, 1968
- Dietary treatment of homocystinuria.Archives of Disease in Childhood, 1966